drugset / Trial / NCT05490563

STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia

NCT05490563

Phase 2/3 Terminated 23 enrolled Seelos Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase 2b/3 double blind, randomized, placebo-controlled trial to assess safety and efficacy of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of adults with spinocerebellar ataxia).

Timeline

Start
2022-06-03
Primary completion
2023-11-24
Completion
2023-11-24

Drugs

EvaluationDrugModalityDoseRoute
Subject SLS-005 Unknown 0.5 g/kg Intravenous
Subject SLS-005 Unknown 0.75 g/kg Intravenous